Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3CNS 1Breast 1

Conditions

Breast Neoplasms 4Small Cell Lung Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Brain Neoplasms 1

Interventions

pembrolizumab 14Gemcitabine 8Docetaxel 7Nivolumab 6durvalumab 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5atezolizumab 4Magnetic Resonance Spectroscopy 4Irinotecan 4sargramostim 3aldesleukin 3Specimen Handling 3Radiotherapy 3Paclitaxel 3Ipilimumab 3Fulvestrant 3Cisplatin 3Carboplatin 3venetoclax 2temsirolimus 2talazoparib 2spartalizumab 2olaparib 2liposomal doxorubicin 2fludarabine phosphate 2cabozantinib 2budigalimab 2avelumab 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × etirinotecan pegol × Breast × Clear all
NCT02312622 2023-12-12

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Stanford University

Phase 2 Completed
27 enrolled 19 charts
BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡